Abnormal liver panel in acute kawasaki disease

Pediatric Infectious Disease Journal

Volumn 30, Issue 2, 2011, Pages 141-144

  Eladawy, Mohammed ^a   Dominguez, Samuel R ^b   Anderson, Marsha S ^b   Glodé, Mary P ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

IVIG resistance; Kawasaki disease; liver function tests

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE;

EID: 79551576898     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f6fe2a     Document Type: Article

References (28)

1. Kawasaki T. Acute febrile mucocutaneus lymph node syndrome; clinical observation of 50 cases. Jpn J Allergy. 1976;16:178-222.
2. Amano S, Hozama F, Hamashima Y. Pathology of Kawasaki disease. II. Distribution and incidence of the vascular lesions. Jpn Circ J. 1979;43: 741-748.
3. Zulian F, Falcini F, Zancan L, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr. 2003;142:731-735.
4. Burns JC, Mason WH, Glode MP, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. J Pediatr. 1991;118:680-686.
5. Valentini P, Ausili E, Schiavino A, et al. Acute cholestasis: atypical onset of Kawasaki disease. Dig Liver Dis. 2008;40:582-584.
6. Elizabath KE, Ahamed MZ, Praveen KS. Atypical relapsing course of Kawasaki disease with hemorrhagic serous effusions and hepatic dysfunction. Indian Pediatr. 2007;44:785-787.
7. Uehara R, Yashiro M, Hayasaka S, et al. Serum alanine aminotransferase concentrations in patients with Kawasaki disease. Pediatr Infect Dis J. 2003;22:839-842.
8. Ting EC, Capparelli E, Billman G, et al. Elevated gamma glutamyl transferase concentration in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998;17:431-432.
9. Newburger J, Takahashi M, Gerber M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-1733.
10. Centenari C, Caprai S, Vitucci P, et al. Hepatic presentation of Kawasaki disease. Dig Liver Dis. 2008;40:A104-A105.
11. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599-610.
12. Ballmer P. Causes and mechanisms of hypoalbuminemia. Clin Nutr. 2001; 20:271-273.
13. Franch-Arcas G. The meaning of hypoalbuminemia in clinical practice. Clin Nutr. 2001;20:265-269.
14. Ohshio G, Furukawa F, Fujiwara H, et al. Hepatomegaly and splenomegaly in Kawasaki disease. Pediatr Pathol. 1985;4:257-264.
15. O'Connor N, Dargan P, Jones A. Hepatocellular damage from non-steroidal anti-inflammatory drugs. Q J Med. 2003;96:787-791.
16. Bertino JS Jr, Willis ED, Reed MD, et al. Salicylate hepatitis: a complication of the treatment of Kawasaki's Disease. Am J Hosp Pharm. 1981;38: 1171-1172.
17. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166: 131-137.
18. Mofenson HC, Greensher J, Molavi M. Gallbladder hydrops: complication of Kawasaki disease. N Y State J Med. 1980;80:249-251.
19. Bader-Meunier B, Hadchouel M, Fabre M, et al. Intrahepatic bile duct damage in children with Kawasaki disease. J Pediatr. 1992;120:750-752.
20. Edwards K, Glick A, Greene H. Intrahepatic cholangitis associated with mucocutaneous lymph node syndrome. J Pediatr Gastroeneterol Nutr. 1985;4:140-142.
21. Falcini F, Resti M, Azzari C, et al. Acute febrile cholestasis as an inaugural manifestation of Kawasaki's disease. Clin Exp Rheumatol. 2000;18:779-780.
22. Terman A, Dalen H, Eaton J, et al. Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover. Ann N Y Acad Sci. 2004;1019:70-77.
23. Shen CT, Wang NK. Antioxidants may mitigate the deterioration of coronary arteritis in patients with Kawasaki disease unresponsive to high-dose intravenous gamma-globulin. Pediatr Cardiol. 2001;22:419-422.
24. Kimura A, Inoue O, Kato H. Serum concentrations of total bile acids in patients with acute Kawasaki syndrome. Arch Pediatr Adolesc Med. 1996; 150:289-292.
25. Cha S, Yoon M, Ahn Y, et al. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease. J Korean Med Sci. 2008; 23:718-722.
26. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153:117-121.
27. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-1148.
28. Sittiwangkul R, Pongprot Y, Silvilairat S, et al. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. Singapore Med J. 2006;47:780-784.